RGC - CIK 0001829667
Regencell Bioscience Holdings Ltd (RGC) reported net income of -$3.58M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$3.58M | +16.7% |
| FY 2024 | -$4.30M | +26.7% |
| FY 2023 | -$5.87M | +21.1% |
| FY 2022 | -$7.45M | -452.9% |
| FY 2021 | -$1.35M | -65.8% |
| FY 2020 | -$812.37K | -107.8% |
| FY 2019 | -$390.99K | - |
Regencell Bioscience Holdings Ltd (RGC) reported net income of -$3.58M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Regencell Bioscience Holdings Ltd's net income declined from -$390.99K to -$3.58M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.